In heavier pediatric SMA patients, intravenous Zolgensma improves motor function.

Published Date: 10 Mar 2024

Results from the most recent phase 3b SMART trial, in which patient weights range from 8.5 kg to 21 kg, confirm the safety and effectiveness of intravenous onasemnogene abeparvovec (Zolgensma; Novartis) in treating spinal muscular atrophy.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Belgian Algorithm Reshapes Endometrial Cancer Care

2.

ASCO: Durvalumab plus FLOT beneficial for resectable gastric, GE junction cancer

3.

Nuclear missile workers are contracting cancer: They blame the bases

4.

On all CAR-T products, the FDA is calling for a new boxed warning.

5.

ASCO Future Focus: Metastatic Breast Cancer: Future Focus from the American Society of Clinical Oncology


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot